Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

A New Jersey judge is calling for a statewide consolidation of all lawsuits filed against the makers of the heartburn medication Reglan that involve claims that the drug caused a serious and debilitating movement disorder known as Tardive Dyskinesia. Judge Eugene J. Codey, Jr., of the Essex County Superior Court, filed the request arguing that the New Jersey court system could better handle the mounting number of lawsuits if they were all centralized in one court. The primary defendant in the lawsuits, Wyeth Pharmaceuticals, is headquartered in New Jersey.

Read the rest of this entry »

Mederi Therapeutics Inc. is launching an innovative new radiofrequency device for the treatment of gastroesophageal reflux disease, also known as GERD. Mederi’s Stretta is a balloon catheter with a needle that delivers radiofrequency energy. The system is inserted into the esophagogastric junction, or the sphincter controlling the entrance of food into the stomach, and prevents stomach acids from backing up into the esophagus. The radiofrequency waves work to restore the function of the valve separating the esophagus from the stomach.

Read the rest of this entry »

The Food and Drug Administration (FDA) has fired off a warning letter to drug maker Salix Pharmaceuticals arguing that some of its marketing materials for Metozolv, an orally dissolving form of metoclopramide for the treatment of acid reflux conditiosn, “are false or misleading because they omit and minimize risk information, broaden the indication of Metozolv ODT, and contain unsubstantiated comparative and other claims.”

The letter goes on to say that “these violations are concerning from a public health perspective because they suggest that Metozolv ODT is safer and more effective than has been demonstrated by substantial evidence or substantial clinical experience, and encourage use in circumstance other than those for which the drug has been shown to be safe and effective.”

Read the rest of this entry »

Melissa Kotlen Nagin is not a fan of the prescription drug Reglan, especially to stimulate milk production in breast feeding mothers. Nagan, a mother of three, is an International Board Certified Lactation Consultant and Registered Lactation Consultant who maintains an active private practice, teaches prenatal breastfeeding classes in New York City, and lectures on lactation topics at The Mount Sinai Hospital in New York City. She has assisted hundreds of women on breastfeeding issues in the past eight years. Lately, she has fielded numerous questions from her clients about how to increase milk supply. She says, “For the majority, aside from increasing stimulation, we talk about going the herbal route; for a smattering, we chat about Domperidone. For NONE do I discuss Reglan.”

Read the rest of this entry »

Researchers from the North Alabama Research Center based in Athens, Ala., are looking for people to participate in clinical trials for a potential new medication to treat gastrointestinal disease, also known as GERD. Persons age 18 to 70 who are still suffering from symptoms of GERD despite treatment with prescription medications are welcome to participate in the clinical trial. Participants must live within 50 miles of the clinic. Those interested can sign up at the Clinical Connection Web site here.

Read the rest of this entry »

Sufferers of gastroesophageal reflux disease, also known as GERD, often experience symptoms such as heartburn and a sour taste in the mouth. But nearly half of all people with GERD have no symptoms except a chronic cough.

Most people dismiss the idea that they even have the acid reflux condition because they have none of the classic symptoms, but many sufferers of chronic cough may find relief when treating themselves for GERD.

Read the rest of this entry »

A team of researchers renowned for their work in colon cancer believe they may have found a better treatment for Barrett’s esophagus and esophageal cancer based on findings from their colon cancer research, according to Science Daily.

Read the rest of this entry »

The U.S. Fifth Circuit Court of Appeals has found in favor with a lower court that patients may sue generic drug makers under state law for failing to provide adequate warnings about potential side effects with their drugs. The ruling extends a 2009 U.S. Supreme Court ruling governing makers of name-brand drugs. The issue of whether generic drug companies should be held liable for not adequately warning consumers has divided several district courts, which can increase the odds of a Supreme Court review in the future, according to U.S. Circuit Judge Patrick Higginbotham.

Read the rest of this entry »

More and more doctors are diagnosing fussy infants with gastroesophageal reflux disease, or GERD, leaving some critics worrying that doctors are over-diagnosing the condition to soothe exasperated mothers.

Read the rest of this entry »

Swiss biotech group Addex Pharmaceuticals announced that its lead drug candidate met expectations in a mid-stage clinical trial in heartburn, setting the company up for a lucrative partnership with a bigger drug maker that would provide much-needed funds for the startup company.

Read the rest of this entry »